



NEURO-ONCOLOGY QUALITY MEASUREMENT SET

This is a summary of the American Academy of Neurology and Society for Neuro-Oncology's neuro-oncology quality measurement set. Please refer to the full measurement set at AAN.com/policy-and-guidelines/quality/quality-measures2/quality-measures/other/ for more information, including the complete set of measurement specifications. These measures use the following formulas to identify quality of care performance.

$$\text{QUALITY OF PATIENT CARE} = \frac{\text{Patients Who Meet Criterion}}{\text{(Eligible Population – Exclusions)}}$$

Multidisciplinary Care Plan Developed for Primary Brain or Spine Tumors

MEASURE PURPOSE: Ensure multidisciplinary care.

TO MEET THE MEASURE: Develop a multidisciplinary tumor board treatment plan for patients with a new diagnosis of primary brain or spine Central Nervous System (CNS) World Health Organization (WHO) grade II-IV tumor.

NUMERATOR: Patients with a multidisciplinary tumor board treatment plan* developed in the 12-month measurement period.

DENOMINATOR: All patients diagnosed in the measurement period with a new diagnosis of primary brain or spine CNS WHO grade II-IV tumor.

EXCLUSION: None

Quality of care provided to your patients with a new diagnosis of grade II-IV primary brain or spine tumor

Molecular Testing in Accordance with World Health Organization Classification of Tumors of the Central Nervous System

MEASURE PURPOSE: Increase rates of molecular testing.

TO MEET THE MEASURE: Perform molecular testing in accordance with most recent WHO classification for patient's initial resection or biopsy of grade II-IV glioma.

NUMERATOR: Patients with molecular testing* performed in accordance with most recent WHO classification flow.

DENOMINATOR: Patients 18 years and older who have had an initial resection or biopsy of grade II-IV glioma.

EXCLUSION:

- Patients with insufficient tissue sample for molecular testing

Quality of care provided to your patients with grade II-IV glioma who had an initial resection or biopsy

Chemotherapy Education and Informed Consent for Brain Tumor Patients

MEASURE PURPOSE: Increase chemotherapy education and informed consent rates.

TO MEET THE MEASURE: Prior to prescribing chemotherapy provide education and obtain an informed consent for patients with a brain tumor.

NUMERATOR: Patients who were provided chemotherapy education* AND for whom informed consent was obtained prior to prescription of chemotherapy.

DENOMINATOR: Patients 18 years and older with a diagnosis of brain tumor who were prescribed chemotherapy outside of a clinical trial.

EXCLUSION:

- Patients that received education and active consent obtained for same chemotherapy prescription in the past 12-month period

Quality of care provided to your patients with a brain tumor prescribed chemotherapy outside of a clinical trial

*See full specifications for additional details at AAN.com/policy-and-guidelines/quality/quality-measures2/quality-measures/other/

Intra-operative or post-operative MRI for gliomas

MEASURE PURPOSE: Ensure MRI completed in a timely manner.

TO MEET THE MEASURE: Obtain a post-operative or intra-operative MRI for patients with a grade III-IV glioma who had a surgical resection.

NUMERATOR: Patients who had a post-operative* gadolinium enhanced MRI of the brain or an intraoperative* MRI of the brain with or without gadolinium.

DENOMINATOR: Patients 18 years and older with a diagnosis of grade III-IV glioma who undergo a surgical resection.

— **EXCLUSIONS:**

- Patients with a contraindication for MRI (i.e., presence of pacemaker, intracranial metal clip, metallic body in the eye, or neurostimulator).
- Patients with a contraindication for receiving gadolinium.
- Patients who undergo surgery for purposes other than cytoreduction (i.e., diagnostic biopsy only).

=

Quality of care provided to your patients with a grade III-IV glioma undergoing a surgical resection

Venous Thromboembolism Events (VTE) Following Primary Brain Tumor Surgery

MEASURE PURPOSE: Reduce the number of VTE following primary brain tumor surgery.

TO MEET THE MEASURE: Count the number of VTE following primary brain tumor surgery.

NUMERATOR: Patients who experience a deep vein thrombosis (DVT) or pulmonary embolism (PE) event during their immediate post-surgical hospitalization, identified on diagnostic testing performed.

DENOMINATOR: All patients who had resection or biopsy of grade III-IV glioma

— **EXCLUSION:**

- DVT or PE present at admission

=

VTE outcomes for your patients following primary brain tumor surgery

*See full specifications for additional details at AAN.com/practice/quality-measures.